The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

Enferm Infecc Microbiol Clin (Engl Ed). 2019 Dec;37(10):634-641. doi: 10.1016/j.eimc.2019.03.001. Epub 2019 Apr 11.
[Article in English, Spanish]

Abstract

Background: The cascade of care of the hepatitisC are complex. The diagnosis of active infection in the same serum sample would simplify the process establishing a rapid access for patients to treatment. Our objective was to estimate the impact on healthcare and economic outcomes of the diagnosis of chronic infection in one-step diagnosis compared to standard diagnosis in Andalusia (8.39 million people).

Methods: A decision tree was developed to estimate the referral of patients with chronic infection, loss of follow-up, access to treatment and costs of the diagnosis of the infection, for both processes. The unit costs (€, 2018) of the health resources (medical visits, antibodies, viral load and genotype), without considering the pharmacological cost, were obtained form public sources in Andalusia.

Results: Of the total estimated population (269,526 patients), 1,389 patients would be referred to the specialised care in the one-step diagnosis and 1,063 in de standard diagnosis, being treated 1,320 and 1,009, respectively. In one-step diagnosis, no negative viral loud patient would be referred to specialist versus 540 with standard diagnosis. One-step diagnosis would generate a cost saving of €184,928 versus standard diagnosis (€15,671,493 vs €15,856,421). When compared one-step diagnosis to standard diagnosis, the savings per patient with positive viral load referred to specialist would be €3,634 (€11,279 vs €14,923).

Conclusion: The one-step diagnosis will achieve an increase in diagnosed patients, will increase the access of chronic patient to treatment and will generate cost savings, demonstrating its efficiency in the system in Andalusia.

Keywords: Cascada de cuidado VHC; Diagnóstico en un paso; HCV cascade of care; Hepatitis C; One-step diagnostic.

MeSH terms

  • Cost-Benefit Analysis*
  • Decision Trees*
  • Health Care Costs*
  • Hepatitis C, Chronic / diagnosis*
  • Hepatitis C, Chronic / economics*
  • Humans